(Q33359764)

26 July 2017

EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy (English)

1 reference

26 July 2017

cervix uterine cancer

1 reference

Li Shen

1

1 reference

26 July 2017

Yongjie Shui

2

1 reference

26 July 2017

Xiaojia Wang

3

1 reference

26 July 2017

Liming Sheng

4

1 reference

26 July 2017

Zhengyan Yang

5

1 reference

26 July 2017

Danfeng Xue

6

1 reference

26 July 2017

Qichun Wei

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

12 August 2008

1 reference

26 July 2017

1 reference

26 July 2017

8

1 reference

26 July 2017

232

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-8-232

26 July 2017

0 references

cites work

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Global cancer statistics, 2002

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

HER2 expression in cervical cancer as a potential therapeutic target

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Modern management of locally advanced cervical carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Tumour therapy with radionuclides: assessment of progress and problems.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Current perspectives on HER2 testing: a review of national testing guidelines

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

The significance of Erb-b2 immunostaining in cervical cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-232

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Erlotinib (OSI-774, Tarceva™), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Chemotherapy for Advanced Non–Small-Cell Lung Cancer

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2519090

Response of metastatic breast cancer to trastuzumab?

31 October 2018

1 reference

12 December 2020

Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy

1 reference

12 December 2020

Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer)

1 reference

12 December 2020

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

12 December 2020

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

12 December 2020

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

12 December 2020

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-8-232

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference